Veterinary Influenza Vaccines


Sustained outbreaks of highly pathogenic influenza in animals increase the risk of reassortment and adaption to humans. This technology describes DNA vaccines against influenza serotypes H5N1, H1N1, H3N2, and H3N8 for poultry, swine and equine. Particularly one vaccine, a trivalent combination of H5N1 immunogens, effectively protects against homologous and heterologous challenges. These vaccines can be delivered intramuscularly or through needle-free delivery mechanism.

Potential Commercial Applications: Competitive Advantages:
Veterinary influenza vaccine specifically designed for poultry, swine and equine.  
  • More efficient and versatile than the conventional inactivated whole-virus vaccines
  • Can be precisely tailored to target one or more strains of avian, swine or equine outbreaks
  • Adaptable to large scale immunization
  • Shorter production time than the current egg-based technology
  • Noninfectious and safe to manipulate and handle
  • Needle-free device delivery elicits robust cellular immune response


Inventors:
Gary Nabel (NIAID)
Zhi-yong Yang (NIAID)
Srinivas Rao (NIAID)
Chih-jen Wei (NIAID)
Wing-pui Kong (NIAID)


Intellectual Property:
US Application No. 61/021,586
PCT Application No. PCT/US2009/031329
US Application No. 12/838,292

Publications:
Rao S, Kong WP, Wei CJ, Yang ZY, Nason M, Styles D, DeTolla LJ, Panda A, Sorrell EM , Song H, Wan H, Ramirez-Nieto GC, Perez D, Nabel GJ. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS ONE 3(6):e2432. Epub 2008 June 18. PubMed: 19293944
Swine and equine publications are being submitted for review.

Licensing Contact:
Cristina Thalhammer-Reyero , Ph.D., M.B.A.
NIH Office of Technology Transfer
Email: thalhamc@mail.nih.gov
Phone: 301-435-4507

OTT Reference No: E-050-2008/0

Updated: Mar-21-2011